Eupraxia Pharmaceuticals Stock Performance
| EPRX Stock | CAD 10.02 0.13 1.31% |
On a scale of 0 to 100, Eupraxia Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of 0.6, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eupraxia Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eupraxia Pharmaceuticals is expected to be smaller as well. Please check Eupraxia Pharmaceuticals' jensen alpha, sortino ratio, maximum drawdown, as well as the relationship between the total risk alpha and treynor ratio , to make a quick decision on whether Eupraxia Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal basic indicators, Eupraxia Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.3 M | |
| Total Cashflows From Investing Activities | -75.2 K |
Eupraxia |
Eupraxia Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 820.00 in Eupraxia Pharmaceuticals on September 30, 2025 and sell it today you would earn a total of 182.00 from holding Eupraxia Pharmaceuticals or generate 22.2% return on investment over 90 days. Eupraxia Pharmaceuticals is generating 0.3889% of daily returns and assumes 3.6648% volatility on return distribution over the 90 days horizon. Simply put, 32% of stocks are less volatile than Eupraxia, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Eupraxia Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eupraxia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eupraxia Pharmaceuticals, and traders can use it to determine the average amount a Eupraxia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1061
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EPRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.66 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Eupraxia Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eupraxia Pharmaceuticals by adding it to a well-diversified portfolio.
Eupraxia Pharmaceuticals Fundamentals Growth
Eupraxia Stock prices reflect investors' perceptions of the future prospects and financial health of Eupraxia Pharmaceuticals, and Eupraxia Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eupraxia Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 429.37 M | ||||
| Shares Outstanding | 50.65 M | ||||
| Price To Book | 6.36 X | ||||
| EBITDA | (33.72 M) | ||||
| Cash And Equivalents | 35.46 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 103.31 K | ||||
| Debt To Equity | 0.42 % | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (29.99 M) | ||||
| Earnings Per Share | (1.20) X | ||||
| Total Asset | 50.24 M | ||||
| Retained Earnings | (131 M) | ||||
About Eupraxia Pharmaceuticals Performance
By examining Eupraxia Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Eupraxia Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Eupraxia Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. EUPRAXIA PHARMACEUTICALS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 19 people.Things to note about Eupraxia Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eupraxia Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (25.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (29.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 17.0% of the company shares are held by company insiders |
- Analyzing Eupraxia Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eupraxia Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eupraxia Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eupraxia Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eupraxia Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eupraxia Pharmaceuticals' stock. These opinions can provide insight into Eupraxia Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.